Amgen IMDELLTRA monitoring requirements have been substantially reduced following a new U.S. Food and Drug Administration (FDA) approval, a change the Thousand Oaks, California-based biotechnology company said will support broader access to the small cell lung cancer therapy in community healthcare settings. Amgen (NASDAQ: AMGN) announced on September 14, 2026 that the FDA approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information, cutting the recommended observation period for the drug’s first two doses.
Under the revised label, patients receiving IMDELLTRA are now monitored for 6 to 8 hours from the start of their first two infusions, down from the previously required 22 to 24 hours. Patients will also undergo a follow-up assessment, including vital signs, on the day after each of these first two doses, corresponding to Cycle 1 Days 2 and 9. The Amgen IMDELLTRA monitoring update applies only to these first two infusions in a newly treated patient’s course.
The change applies specifically to people living with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of the disease in which most patients experience progression after first-line treatment. The updated Amgen IMDELLTRA monitoring requirements could translate into substantially less time spent in a healthcare facility during the initial treatment period, Amgen said, particularly for community oncology practices, where an estimated 80% to 85% of U.S. cancer patients receive care.
Amgen IMDELLTRA Monitoring Update Aims to Ease Burden on Patients and Community Practices
Discussing the Amgen IMDELLTRA monitoring update, Jay Bradner, M.D., executive vice president of Research and Development, Artificial Intelligence and Data at Amgen, said patients being treated for small cell lung cancer are already navigating an aggressive and difficult-to-treat disease, and that the time required to receive and monitor treatment adds to the burden for patients and care centers alike. He described the approval as an important step toward simplifying care for people living with ES-SCLC, noting that shortening the observation period for the initial doses may help address practical barriers to administering the therapy and allow more patients to receive treatment closer to home.
Reacting to the Amgen IMDELLTRA monitoring update, David M. Waterhouse, MD, MPH, FASCO, a medical oncologist and hematologist at Oncology Hematology Care in Cincinnati, Ohio, said community oncology practices care for patients where they live, which matters for people managing small cell lung cancer. He noted that these patients are often very sick, and that traveling long distances or spending extended time in a healthcare setting can be difficult for them and their families. According to Waterhouse, the reduced monitoring period may make the therapy more feasible to administer in community practices, helping more patients stay within their local care network.
What Changed and What Stayed the Same in the Amgen IMDELLTRA Monitoring Schedule
The Amgen IMDELLTRA monitoring update is limited to the first two doses of treatment, now requiring only 6 to 8 hours of monitoring from the start of infusion in an appropriate healthcare setting. Beyond this change and the addition of a follow-up patient assessment, the remainder of the monitoring and supportive care schedule is unchanged. Patients continue to be monitored for 6 to 8 hours following the third dose, administered on Cycle 1 Day 15, and throughout Cycle 2. Monitoring time then decreases to 3 to 4 hours for Cycles 3 and 4, and to 2 hours for Cycle 5 and all subsequent doses.
Patients are also advised to remain within one hour of an appropriate healthcare setting for a total of 48 hours from the start of infusion following the Cycle 1 Day 1 and Cycle 1 Day 8 doses, accompanied by a caregiver. Amgen said the updated requirements reflect an evolution in how IMDELLTRA is administered and reinforce the company’s stated commitment to addressing the real-world needs of people living with cancer, even as the core safety monitoring framework for higher-risk early doses remains in place. The Amgen IMDELLTRA monitoring schedule beyond these first two doses continues to scale down as treatment progresses.
The table below summarizes the revised Amgen IMDELLTRA monitoring schedule as outlined in the updated Prescribing Information.
Table 1: IMDELLTRA Post-Infusion Monitoring Schedule
| Treatment Timepoint | Monitoring Duration | Additional Requirement |
|---|---|---|
| Cycle 1 Day 1 (Dose 1) | 6 to 8 hours from start of infusion | Remain within 1 hour of care setting for 48 hours; caregiver required; follow-up assessment Day 2 |
| Cycle 1 Day 8 (Dose 2) | 6 to 8 hours from start of infusion | Remain within 1 hour of care setting for 48 hours; caregiver required; follow-up assessment Day 9 |
| Cycle 1 Day 15 (Dose 3) and Cycle 2 | 6 to 8 hours from start of infusion | Standard post-infusion observation |
| Cycles 3 and 4 | 3 to 4 hours from start of infusion | Standard post-infusion observation |
| Cycle 5 and beyond | 2 hours from start of infusion | Standard post-infusion observation |
Amgen IMDELLTRA Monitoring Update Follows Phase 3 Survival Results in First-Line ES-SCLC
The Amgen IMDELLTRA monitoring update follows recent positive topline overall survival data from the Phase 3 DeLLphi-305 study evaluating IMDELLTRA in combination with Imfinzi in first-line extensive-stage small cell lung cancer. Amgen said reduced post-infusion monitoring is being evaluated in several ongoing studies across additional indications and lines of therapy, which the company said will continue to inform the potential for further reductions in monitoring requirements over time.
IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing small cell lung cancer cells through formation of a cytolytic synapse. DLL3 is expressed on the surface of SCLC cells in an estimated 85% to 96% of patients with the disease, while remaining minimally expressed on healthy cells. IMDELLTRA is indicated in the United States for adult patients with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy.
Small cell lung cancer accounts for approximately 13% to 15% of the more than 2.6 million lung cancer cases diagnosed worldwide each year, according to figures cited in the release. Despite initially high response rates to first-line platinum-based chemotherapy, most patients relapse within months and require subsequent treatment.
Table 2: Referenced Clinical Trials
| Clinical Trial | Role in Pooled Safety Data | Registry Reference |
|---|---|---|
| DeLLphi-300 | Contributed to 473-patient pooled safety population | ClinicalTrials.gov |
| DeLLphi-301 | Contributed to 473-patient pooled safety population | ClinicalTrials.gov |
| DeLLphi-304 | Contributed to 473-patient pooled safety population | ClinicalTrials.gov |
| DeLLphi-305 | Phase 3 first-line ES-SCLC combination study; recent topline overall survival results announced separately | ClinicalTrials.gov |
Safety Profile Behind the Amgen IMDELLTRA Monitoring Decision
The Amgen IMDELLTRA monitoring requirements exist because the therapy carries a boxed warning for cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), both of which can be life-threatening or fatal. In the pooled safety population of 473 patients across the DeLLphi-300, DeLLphi-301 and DeLLphi-304 trials, CRS occurred in 57% of patients, with the large majority classified as Grade 1 or Grade 2. Neurologic toxicity occurred in 65% of patients, with Grade 3 or higher events in 7%, including fatal events in 0.2% of patients. Signs and symptoms consistent with ICANS occurred in 10% of patients.
Amgen reported that among patients who experienced CRS, 73% had the reaction after the first dose and 60% after the second dose, underscoring why the initial two infusions previously required extended observation. The most common adverse reactions occurring in 20% or more of patients were CRS, fatigue, decreased appetite, dysgeusia, pyrexia, constipation, musculoskeletal pain and nausea. The data tables below summarize key safety findings from the pooled analysis.
Table 3: Most Common Adverse Reactions (Pooled Safety Population, n=473)
| Adverse Reaction | Any Grade | Grade 3 or Higher |
|---|---|---|
| Cytokine release syndrome | 57% | 1.9% (Grade 3/4) |
| Fatigue | 48% | Not disclosed |
| Decreased appetite | 38% | Not disclosed |
| Dysgeusia | 34% | Not disclosed |
| Pyrexia | 33% | Not disclosed |
| Constipation | 31% | Not disclosed |
| Musculoskeletal pain | 31% | Not disclosed |
| Nausea | 25% | Not disclosed |
able 4: Additional Safety Signals (Pooled Safety Population, n=473)
| Safety Category | Incidence |
|---|---|
| Neurologic toxicity (any grade) | 65% |
| Neurologic toxicity (Grade 3+) | 7% |
| ICANS (any presentation) | 10% |
| Infections (any grade) | 43% |
| Infections (Grade 3/4) | 14% |
| Decreased hemoglobin (any grade) | 56% |
| Decreased platelets (any grade) | 30% |
| Elevated AST (any grade) | 43% |
| Elevated ALT (any grade) | 39% |
Dosing follows a step-up schedule of 1 mg on Cycle 1 Day 1, followed by 10 mg on Days 8 and 15, then every two weeks thereafter until disease progression or intolerable toxicity, administered as a one-hour intravenous infusion. Complete blood counts, liver enzymes and bilirubin are evaluated prior to each dose through Cycle 5 Day 15, and prior to Day 1 of each cycle from Cycle 6 onward. Amgen said IMDELLTRA must be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions, including CRS and ICANS, and that patients and caregivers should be counseled on relevant signs and symptoms prior to discharge.
Amgen, which helped establish the biotechnology industry more than 45 years ago from its Thousand Oaks headquarters, is a component of the Dow Jones Industrial Average and the Nasdaq-100 Index. Media inquiries may be directed to Brianna Wilkins, and investor inquiries to Casey Capparelli, both listed in the company’s September 14, 2026 announcement. Full prescribing information, including boxed warnings, is available through Amgen’s regulatory filings.
